Filing Flows › Tandem Diabetes Care (TNDM) › Q3 2026 › vs Q3 2025
Tandem Diabetes Care (TNDM) Q3 2026 vs Q3 2025 (year over year)
Tandem Diabetes Care's revenue rose $34.4M (+14%) from $249M in Q3 2025 to $284M in Q3 2026. The biggest changes: Supplies and other +$29.6M (+21%); Pump +$4.8M (+4%).
Tandem Diabetes Care, Q3 2026: revenue $284M (+14% year over year), operating margin -0.8%, net loss $7.1M, operating cash flow −$819K. The chart draws each line against Q3 2025, the increases inside each band.
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Supplies and other | $169M | $139M | $29.6M | +21% |
| Pump | $115M | $110M | $4.8M | +4% |
| Revenue | $284M | $249M | $34.4M | +14% |
| Income tax benefit | $608K | $4.0M | −$3.4M | -85% |
| Net loss | $7.1M | $21.2M | −$14.1M | -67% |
| Costs & expenses | $291M | $274M | $17.0M | +6% |
| Operating costs | $286M | $272M | $13.9M | +5% |
| Interest & other, net | $5.3M | $2.3M | $3.0M | +134% |
| Cost of revenue | $123M | $115M | $8.3M | +7% |
| Research & development | $48.8M | $48.7M | $131K | +0.3% |
| SG&A | $114M | $108M | $5.5M | +5% |
| Operating cash sources | $21.2M | $17.4M | $3.9M | +22% |
| Depreciation & amortization | $4.5M | $4.5M | $20K | +0.4% |
| Share-based compensation | $15.9M | $21.1M | −$5.2M | -25% |
| Cash used in operations | $819K | −$8.3M | $9.1M | — |
| Net loss absorbed | $7.1M | $21.2M | −$14.1M | -67% |
| Working capital & other | $14.1M | −$3.8M | $17.9M | — |
Questions
How much did Tandem Diabetes Care's revenue grow year over year in Q3 2026?
Tandem Diabetes Care's revenue rose $34.4M (+14%) from $249M in Q3 2025 to $284M in Q3 2026.
What drove Tandem Diabetes Care's revenue change in Q3 2026?
Supplies and other +$29.6M (+21%); Pump +$4.8M (+4%).